Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03726879
Title A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer (IMpassion050)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

Her2-receptor positive breast cancer

Therapies

Cyclophosphamide + Doxorubicin

Atezolizumab + Cyclophosphamide + Doxorubicin

Atezolizumab + Paclitaxel + Pertuzumab + Trastuzumab

Atezolizumab + Pertuzumab + Trastuzumab

Pertuzumab + Trastuzumab

Paclitaxel + Pertuzumab + Trastuzumab

Age Groups: adult | senior
Covered Countries USA | ITA | ESP | DEU | CAN


No variant requirements are available.